Skip to main content
Evidence Snapshot

Lanosterol 14-alpha demethylase

CHEMBL1780 SINGLE PROTEIN Candida albicans (strain SC5314 / ATCC MYA-2876) (Yeast)
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:14:01Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1780
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Lanosterol 14-alpha demethylase as ChEMBL target CHEMBL1780, mapped to UniProt P10613. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Lanosterol 14-alpha demethylase
SINGLE PROTEIN · Candida albicans (strain SC5314 / ATCC MYA-2876) (Yeast)
As of 2026-09-14
ChEMBL target ID
CHEMBL1780
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P10613
Lanosterol 14-alpha demethylase
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Lanosterol 14-alpha demethylase matters

As of 2026-09-14

Lanosterol 14-alpha demethylase is reviewed as Lanosterol 14-alpha demethylase (UniProt P10613); Lanosterol 14-alpha demethylase shows approved-linked disease relevance led by tinea pedis. 5 more disease programs remain visible in the same review block.; 11 linked drugs keep this evidence frame grounded.; the current evidence base includes 6 approved drugs, 182 compounds, and 355 assays, with lead potency reaching pChEMBL 8.0.

Disease context
tinea pedis

Lanosterol 14-alpha demethylase shows approved-linked disease relevance led by tinea pedis. 5 more disease programs remain visible in the same review block. 11 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include CLOTRIMAZOLE, ECONAZOLE NITRATE, FLUCONAZOLE.

Start review with tinea pedis because it currently carries approved-linked support. Linked drugs include CLOTRIMAZOLE, ECONAZOLE NITRATE, FLUCONAZOLE, ITRACONAZOLE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 11 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 6 approved drugs, 182 compounds, and 355 assays for this target. The dominant activity type is IC50. CHEMBL4128885 is the current potency anchor at pChEMBL 8.0.

Use CHEMBL4128885 as the tractability anchor when discussing potency (pChEMBL 8.0).

Activity source · ChEMBL 36 via Core Engine
6 approved pChEMBL 8.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Lanosterol 14-alpha demethylase matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P10613, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why tinea pedis is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

182
Total Compounds
355
Total Assays
6
Approved Drugs
IC50: 35.0, KD: 11.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4128885
 8.0 Kd —
No preferred name
CHEMBL4127493
 7.9 Kd —
No preferred name
CHEMBL4129161
 7.9 Kd —
No preferred name
CHEMBL4128615
 7.6 Kd —
No preferred name
CHEMBL5555392
 7.4 IC50 —

Approved Drugs

Structure Compound First Approval
POSACONAZOLE
CHEMBL1397
 2005
VORICONAZOLE
CHEMBL638
 2002
FLUCONAZOLE
CHEMBL106
 1990
KETOCONAZOLE
CHEMBL157101
 1981
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:14:01Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1780